Vaxiion receives US patent for minicell-based therapeutics
The patent covers compositions of matter related to the antibody-based targeted delivery of biologically active compounds (including therapeutics) using Vaxiion’s minicell-delivery platform technology. Vaxiion’s targeted therapeutic delivery platform
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.